Jan Johannessen, a director at Twist Bioscience Corp (NASDAQ:TWST), executed and sold shares of the company’s common stock on May 12, 2026, according to a recent Form 4 filing with the Securities and Exchange Commission.
The transactions involved Mr. Johannessen selling 12,000 shares of common stock for a total value of $673,440. The shares were sold at a price of $56.12 per share. Concomitantly, Mr. Johannessen acquired 12,000 shares of common stock through the exercise of employee stock options at a price of $14.00 per share, amounting to $168,000.The sale comes as Twist Bioscience shares have surged 84% over the past year, though the stock currently trades at $52.95, which InvestingPro analysis suggests is above its Fair Value—placing it on the most overvalued list. The company’s beta of 2.23 indicates high volatility, one of 10+ InvestingPro Tips available for deeper analysis.
The options exercised were part of an employee stock option grant where one-third of the shares vested and became exercisable on October 30, 2019, with an additional one-third vesting annually thereafter, contingent on Mr. Johannessen’s continuous service.
Following these transactions, Mr. Johannessen directly holds 17,754 shares of Twist Bioscience common stock.
In other recent news, Twist Bioscience reported its second-quarter earnings for fiscal year 2026, revealing robust revenue growth but a significant earnings per share (EPS) miss. The company achieved total revenues of $111 million, marking a 19% increase compared to the previous year and surpassing the consensus estimate of $108 million. However, the EPS came in at -$0.71, falling short of the anticipated -$0.48. Despite the EPS miss, the revenue beat contributed to a positive outlook among investors. In response to the revenue performance, TD Cowen raised its price target for Twist Bioscience stock from $58 to $68, while maintaining a Buy rating. The firm’s decision reflects confidence in the company’s financial trajectory, emphasizing the importance of revenue achievements over EPS shortcomings. These developments highlight the mixed financial performance of Twist Bioscience, with strong revenue growth offsetting the impact of the EPS miss.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.